Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium voltage-gated channel auxiliary subunit gamma 3 (CACNG3) is a type I transmembrane protein that serves as an auxiliary (gamma) subunit for voltage-gated calcium channels and also functions as a regulatory protein for AMPA-type glutamate receptors, known as a transmembrane AMPAR regulatory protein (TARP). CACNG3 plays a crucial role in stabilizing the inactive state of voltage-gated calcium channels and modulates AMPA receptor trafficking to the membrane and their gating properties, thereby regulating synaptic transmission and neuronal excitability. The gene is primarily expressed in the brain and is associated with epilepsy syndromes (notably juvenile absence epilepsy), as well as implicated in neurodevelopmental disorders and potentially glioma prognosis[1][2][3][4][6]. No direct drug interactions are currently annotated, but its central role in synaptic function and disease association make it a candidate target for future therapeutics.
Modulation of neural excitability by regulating ion channel function. Influence on AMPA receptor surface expression and functional kinetics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium voltage-gated channel auxiliary subunit gamma 3 (CACNG3).